Study of Combination of Metronomic Oral Vinorelbine and Sorafenib in Patients With Advanced Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
Targeting the blood supply of cancer, called anti-angiogenesis is a new but proven treatment
strategy. There are two ways of achieving this effect. The first way to specifically target
the molecular pathways that promote new blood vessel formation in cancer. An example of such
an agent is sorafenib, which is an oral agent and which is already in use worldwide for the
treatment of kidney and liver cancers. The second way is to target the cells lining the blood
vessels by using low dose of chemotherapy agents administered at frequent intervals. This
strategy is called metronomic chemotherapy. It is possible that combining agents like
sorafenib and metronomic chemotherapy may further enhance anti-cancer effects. This study
aims to determine the optimal way of combining oral vinorelbine in metronomic doses and
sorafenib. Oral vinorelbine is a chemotherapy agent that is already approved for use in
cancer treatment such as lung cancer. By combining both oral anti-cancer agents to optimize
their anti-angiogenic effects in this study, the potential benefit to the patients can be
tremendous and far-reaching. Special radiologic imagings and blood tests will be incorporated
into this study to help further the understanding of the anti-angiogenic processes of both
agents.